Form Type:  SC 13D/A
Filing Date:  12/17/2014 
CIK:  0001060736 
Address:  21823 30TH DRIVE SE
City, State, Zip:  BOTHELL, Washington 98021 
Telephone:  (425) 527-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
1.42 (0.84%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
Trade SGEN now with 

© 2020  
Description of Business
Seattle Genetics is a biotechnology company that develops and commercializes therapies targeting cancer. We are commercializing ADCETRIS®, or brentuximab vedotin, for the trbreatment of certain CD30-expressing lymphomas, and PADCEVTM, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers. We are also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Many of our programs, including ADCETRIS and PADCEV, are based on our antibody-drug conjugate, or ADC, technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCETRIS is commercially available in more than 70 countries worldwide. We commercialize ADCETRIS in the U.S.
Register and access this filing in: